Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

“Biofilm Doesn’t Grow Overnight — It Grows on Weak Monitoring” Microbial Contamination & Biofilm Formation in PW Systems



1. Introduction

Purified Water systems rarely fail because of equipment — they fail quietly due to biofilm development, poor loop design, and missing microbial trending.

Evaluating existing batch record review processes to enhance compliance, accuracy, and process efficiency.

During a project in a Pharma South American company, we discovered alarming microbial deviations — but no investigation or trending. The system was “validated” — but already degrading.

 

2. The Hidden Risk: Slow Microbial Growth

Common mistakes we found:

  • Low flow velocity (<1 m/s) — perfect for biofilm development
  • Sanitization not linked to trending data
  • No alert/action limits for microorganisms
  • Dead legs longer than 1.5 × diameter
  • Deviations closed without root cause analysis

Impact: Batch quality becomes unpredictable — and patient safety is put at risk.

 

3. Self-Diagnostic — Is Your System at Risk?

Yes/No Question

  • Do you trend microbial data weekly or monthly?
  • Are alert/action limits defined scientifically?
  • Is flow velocity monitored?
  • Is sanitization frequency tied to data?
  • Are dead legs controlled & documented?

If you scored 3+ YES — your system may already be degrading.

 

4. Real Case:

Real case: We identified biofilm signs in a PW loop that had passed validation only 6 months earlier. The issue wasn’t microbiology — it was design + monitoring failure.

 

5. Compliance Clarity

Regulation Expectation

  • USP <1231> Flow velocity ≥ 1–2 m/s recommended
  • EMA Annex 15 Microbial control must be justified
  • FDA 211.63 Equipment must prevent contamination
  • ISO 19458 Sampling method must prevent artifact contamination

 

6. Action Plan

  • ✔ Control flow velocity (≥1 m/s)
  • ✔ Map/decrease dead legs
  • ✔ Create microbial trending dashboard
  • ✔ Implement alert/action limits
  • ✔ Run preventive sanitization — not reactive

 

7. Final Leadership Thought

Biofilm is not a contamination.

It’s a consequence of neglect.

Picture of Alireza Zarei

Alireza Zarei

Alireza Zarei is the founder and CEO of Zamann Pharma Support GmbH in Germany. He pairs 20 years in GMP—beginning in a lab in 2005—with front-line global project delivery for companies such as Boehringer Ingelheim, Roche, BioNTech, Takeda, Fresenius Medical Care, Biotest, ratiopharm and others. He focuses on innovative validation and qualification procedures, master data management strategies, end-to-end LIMS implementation and care, with pragmatic advice on general Quality Management topics and management level OpEx consulting. Together with his team he also created Pharmuni.com as the leading GMP learning platform in the industry.